<DOC>
	<DOCNO>NCT01294800</DOCNO>
	<brief_summary>This study evaluate efficacy range preladenant dos compare placebo participant moderate severe Parkinson 's disease ( PD ) experience motor fluctuation receive stable dose levodopa ( L-dopa ) , measure `` '' time . Participants continue receive stable regimen L-dopa plus adjunct medication study prescribed physician . Several class adjunct medication may use , include Amantadine , anticholinergic , dopa decarboxylase inhibitor , dopamine agonist . Primary Hypothesis : At least 10 mg twice daily dose preladenant superior placebo measure change Baseline Week 12 mean `` '' time .</brief_summary>
	<brief_title>A Dose Finding Study Preladenant ( SCH 420814 ) Treatment Parkinson 's Disease ( PD ) Japanese Patients ( P06402 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Must diagnosis idiopathic PD base United Kingdom Parkinson 's Disease Society Brain Bank Criteria , judge moderate severe Must receive prior therapy Ldopa 1 year Screening Must stable , optimal dopaminergic treatment regimen , define maximum therapeutic effect achieve available antiParkinsonian treatment , least 4 week immediately randomization If receive one follow adjunctive treatment : amantadine , anticholinergic , catecholOmethyltransferase inhibitor , dopa decarboxylase inhibitor , dopamine agonist , entacapone , Ldopa , must stable regimen treatment least 4 week immediately randomization Hoehn Yahr stage must ≥ 2.5 ≤ 4 follow optimum titration treatment medication Screening Must experience motor fluctuation without dyskinesia follow optimum titration treatment medication within 4 week immediately Screening Must experience minimum 2 hours/day `` '' time estimate investigator support symptom diary ( Daily Diary ) Diary Training Visit With without help caregiver , must capable maintain accurate complete symptom diary ( Daily Diary ) assess Diary Training Visit Must result Screening clinical laboratory test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) within normal limit clinically acceptable investigator Screening Must result physical examination within normal limit clinically acceptable limit investigator Must able adhere dose visit schedule Females childbearing potential must negative serum pregnancy test ( human chorionic gonadotropin [ hCG ] ) Screening must agree use medically accept method contraception receive protocolspecified medication 2 week stop medication Must form druginduced atypical parkinsonism , cognitive impairment , bipolar disorder , schizophrenia , psychotic disorder Must surgery PD Must untreated major depressive disorder meeting Diagnostic Statistical Manual Mental Disorders IV Text Revision ( DSMIVTR ) criterion Must imminent risk selfharm harm others , investigator 's opinion base clinical interview Must participate study use preladenant Must allergy/sensitivity preladenant excipients Must use investigational drug participate clinical trial within 90 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
</DOC>